ADRI (Alzheimer's Disease Risk Index)
Power-Stem's patented inspection technology utilizes advanced Enzyme-Linked Immunosorbent Assay (ELISA) tools to accurately measure the concentration of oxidative proteins disorder (GAPDH) associated with neuronal decay, providing a precise assessment of the risk for Alzheimer's disease.
With a clinical accuracy rate of 95.74% and high sensitivity in detecting this chronic neurological disorder, the ADRI inspection patent has received global patent authorization, being a trailblazer in Alzheimer's disease analysis.
Taiwan Patent
Japan Patent
China Patent
US Patent
